Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematologic abnormalities associated with vidarabine.

R A Lyon, S Swigart

    Drug Intelligence & Clinical Pharmacy
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    In vitro pharmacology of ambroxol: Potential serotonergic sites of action.

    Life sciences·2018
    Same author

    Causes of prematurity; influence of uterine bleeding on the incidence of prematurity.

    American journal of diseases of children (1911)·2010
    Same author

    Causes of prematurity; influence of infections, chronic disorders and accidents on the incidence of prematurity.

    American journal of diseases of children (1911)·2010
    Same author

    Causes of prematurity; influence of toxemia on the incidence of prematurity.

    American journal of diseases of children (1911)·2010
    Same author

    The onset of ovulation during the puerperium.

    California medicine·2010
    Same author

    The use of penicillin in the treatment of subacute bacterial endocarditis in children.

    The Journal of pediatrics·2010

    High-dose vidarabine for neonatal herpes simplex infection may cause hematologic abnormalities, including decreased hematocrit and platelets. Monitoring blood counts is crucial during treatment, especially with doses exceeding 15 mg/kg/d.

    Area of Science:

    • Neonatal medicine
    • Pharmacology
    • Hematology

    Background:

    • Herpes simplex virus infections are a serious concern in neonates.
    • Vidarabine is an antiviral medication used for treating such infections.

    Observation:

    • A neonate treated with high-dose vidarabine (30 mg/kg/d) for herpes simplex infection developed hematologic abnormalities.
    • Specifically, a decrease in hematocrit and platelet count was observed.

    Findings:

    • High-dose vidarabine administration may be associated with significant hematologic changes in neonates.
    • The observed abnormalities included reduced hematocrit and platelet levels.

    Implications:

    • Close monitoring of hematologic indices is essential during vidarabine therapy in neonates.

    Related Experiment Videos

  • Doses of vidarabine greater than 15 mg/kg/d warrant careful consideration due to potential adverse hematologic effects.